» Articles » PMID: 31771601

A Phase I/II Trial Comparing Autologous Dendritic Cell Vaccine Pulsed Either with Personalized Peptides (PEP-DC) or with Tumor Lysate (OC-DC) in Patients with Advanced High-grade Ovarian Serous Carcinoma

Abstract

Background: Most ovarian cancer patients are diagnosed at a late stage with 85% of them relapsing after surgery and standard chemotherapy; for this reason, new treatments are urgently needed. Ovarian cancer has become a candidate for immunotherapy by reason of their expression of shared tumor-associated antigens (TAAs) and private mutated neoantigens (NeoAgs) and the recognition of the tumor by the immune system. Additionally, the presence of intraepithelial tumor infiltrating lymphocytes (TILs) is associated with improved progression-free and overall survival of patients with ovarian cancer. The aim of active immunotherapy, including vaccination, is to generate a new anti-tumor response and amplify an existing immune response. Recently developed NeoAgs-based cancer vaccines have the advantage of being more tumor specific, reducing the potential for immunological tolerance, and inducing robust immunogenicity.

Methods: We propose a randomized phase I/II study in patients with advanced ovarian cancer to compare the immunogenicity and to assess safety and feasibility of two personalized DC vaccines. After standard of care surgery and chemotherapy, patients will receive either a novel vaccine consisting of autologous DCs pulsed with up to ten peptides (PEP-DC), selected using an agnostic, yet personalized, epitope discovery algorithm, or a sequential combination of a DC vaccine loaded with autologous oxidized tumor lysate (OC-DC) prior to an equivalent PEP-DC vaccine. All vaccines will be administered in combination with low-dose cyclophosphamide. This study is the first attempt to compare the two approaches and to use NeoAgs-based vaccines in ovarian cancer in the adjuvant setting.

Discussion: The proposed treatment takes advantage of the beneficial effects of pre-treatment with OC-DC prior to PEP-DC vaccination, prompting immune response induction against a wide range of patient-specific antigens, and amplification of pre-existing NeoAgs-specific T cell clones. Trial registration This trial is already approved by Swissmedic (Ref.: 2019TpP1004) and will be registered at http://www.clinicaltrials.gov before enrollment opens.

Citing Articles

Tumor Neoepitope-Based Vaccines: A Scoping Review on Current Predictive Computational Strategies.

Rocha L, Guimaraes P, Carvalho M, Ruiz J Vaccines (Basel). 2024; 12(8).

PMID: 39203962 PMC: 11360805. DOI: 10.3390/vaccines12080836.


Engineering Challenges and Opportunities in Autologous Cellular Cancer Immunotherapy.

Foley C, Swan S, Swartz M J Immunol. 2024; 212(2):188-198.

PMID: 38166251 PMC: 11155266. DOI: 10.4049/jimmunol.2300642.


Identification of Tumor Antigens and Immune Subtypes of High-grade Serous Ovarian Cancer for mRNA Vaccine Development.

Wu Y, Li Z, Lin H, Wang H J Cancer. 2023; 14(14):2655-2669.

PMID: 37779866 PMC: 10539400. DOI: 10.7150/jca.87184.


Peptide Vaccines as Therapeutic and Prophylactic Agents for Female-Specific Cancers: The Current Landscape.

Lekshmy M, Dhanya C, Smrithi J, Sindhurani J, Vandanamthadathil J, Veettil J Pharmaceuticals (Basel). 2023; 16(7).

PMID: 37513965 PMC: 10383774. DOI: 10.3390/ph16071054.


Cancer vaccines based on whole-tumor lysate or neoepitopes with validated HLA binding outperform those with predicted HLA-binding affinity.

Fritah H, Graciotti M, Lai-Lai Chiang C, Huguenin-Bergenat A, Petremand R, Ahmed R iScience. 2023; 26(4):106288.

PMID: 36950115 PMC: 10025090. DOI: 10.1016/j.isci.2023.106288.


References
1.
Shih I, Kurman R . Ovarian tumorigenesis: a proposed model based on morphological and molecular genetic analysis. Am J Pathol. 2004; 164(5):1511-8. PMC: 1615664. DOI: 10.1016/s0002-9440(10)63708-x. View

2.
Bassani-Sternberg M, Digklia A, Huber F, Wagner D, Sempoux C, Stevenson B . A Phase Ib Study of the Combination of Personalized Autologous Dendritic Cell Vaccine, Aspirin, and Standard of Care Adjuvant Chemotherapy Followed by Nivolumab for Resected Pancreatic Adenocarcinoma-A Proof of Antigen Discovery Feasibility in Three.... Front Immunol. 2019; 10:1832. PMC: 6694698. DOI: 10.3389/fimmu.2019.01832. View

3.
Palucka A, Ueno H, Connolly J, Kerneis-Norvell F, Blanck J, Johnston D . Dendritic cells loaded with killed allogeneic melanoma cells can induce objective clinical responses and MART-1 specific CD8+ T-cell immunity. J Immunother. 2006; 29(5):545-57. DOI: 10.1097/01.cji.0000211309.90621.8b. View

4.
Lawrence M, Stojanov P, Polak P, Kryukov G, Cibulskis K, Sivachenko A . Mutational heterogeneity in cancer and the search for new cancer-associated genes. Nature. 2013; 499(7457):214-218. PMC: 3919509. DOI: 10.1038/nature12213. View

5.
Carreno B, Magrini V, Becker-Hapak M, Kaabinejadian S, Hundal J, Petti A . Cancer immunotherapy. A dendritic cell vaccine increases the breadth and diversity of melanoma neoantigen-specific T cells. Science. 2015; 348(6236):803-8. PMC: 4549796. DOI: 10.1126/science.aaa3828. View